The race for a COVID-19 vaccine
On the back of our recent Covid-19 calls with the Lancet Infectious Diseases, and Roche on testing, it’s clear that an area of great interest for investors currently is that of vaccines and their availability. We are delighted to have hosted a call with vaccine expert Professor Paul Heath, to discuss the following themes:
- What are the difficulties in developing a vaccine for this particular disease?
- What are the advantages and disadvantages of the various approaches being trialled?
- How significant is the progress made thus far?
- What ways can we run pivotal studies to accelerate the time to approval?
- How fast could a successful vaccine be scaled up?
About our Speaker
Background: Professor Heath is a paediatric infectious disease consultant at St George’s, University of London and St George’s University Hospitals NHS Foundation Trust with a specialist interest in vaccinology. His research experience is in the epidemiology of vaccine preventable diseases, clinical vaccine trials in at-risk groups, including pregnant women, and perinatal infections. He has published over 275 papers in these areas.
Expertise in COVID-19: Professor Heath is a globally recognised opinion leader on infectious disease vaccination and is playing an important role in the development of a COVID-19 vaccine. His site is participating in the trials of the University of Oxford and Imperial College COVID-19 vaccines. He recently presented at US listed Moderna’s Vaccine investor day in April of this year.
Click below to listen the full conference call. Please contact CIR@liberum.com for the password.
*The views in these audio recordings are of Professor Paul Heath
This communication is for use only by a person or entity that qualifies as a "Professional Client" or "Eligible Counterparty" within the meaning of the FCA's rules. It is intended for use only by persons having professional experience in matters relating to investments. Any other person who receives this should not act on the contents. Disclaimer here.